These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 8998787)

  • 1. [Potassium channel activators: hemodynamic effects at the systemic and coronary level].
    Perrone Filardi P; Chiariello M
    Cardiologia; 1995 Dec; 40(12 Suppl 1):87-9. PubMed ID: 8998787
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy.
    Krumenacker M; Roland E
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S93-102. PubMed ID: 1282184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical use of potassium channel activators in angina pectoris: efficacy and tolerance].
    Specchia G; Marsico F; Micheletti T; Bona M
    Cardiologia; 1995 Dec; 40(12 Suppl 1):91-5. PubMed ID: 8998788
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of the new nitrate ester ITF 296 on coronary and systemic hemodynamics in the conscious dog: comparison with nitroglycerin and nicorandil.
    Ueno A; Bergamaschi M; Gromo G; Nonaka K; Mizrahi J
    J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S13-20. PubMed ID: 8839221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pinacidil but not nicorandil opens ATP-sensitive K+ channels and protects against simulated ischemia in rabbit myocytes.
    Critz SD; Liu GS; Chujo M; Downey JM
    J Mol Cell Cardiol; 1997 Apr; 29(4):1123-30. PubMed ID: 9160864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nicorandil on large epicardial coronary artery in conscious dogs.
    Yamada A; Tomoike H; Hayashi Y; Nishijima H; Nakamura M
    Arzneimittelforschung; 1987 Nov; 37(11):1252-5. PubMed ID: 2964242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [K-channel activators and cardioprotection].
    Specchia G; Marsico F; Laudisa ML
    Cardiologia; 1993 Dec; 38(12 Suppl 1):453-7. PubMed ID: 8020047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Potassium agonists].
    Hellwig B
    Med Monatsschr Pharm; 1994 Jun; 17(6):164-7. PubMed ID: 8052166
    [No Abstract]   [Full Text] [Related]  

  • 9. Systemic and coronary hemodynamic effects of JTV-506, a novel potassium channel opener, in conscious dogs: comparison with cromakalim and nicorandil.
    Zhang S; Sakai K; Hasuo H; Furuta K; Ureshino H; Shibata O; Sumikawa K
    Res Commun Mol Pathol Pharmacol; 1999; 105(1-2):115-27. PubMed ID: 10850375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary haemodynamics and vasodilatory profile of a potassium channel opener in patients with coronary artery disease.
    Suryapranata H
    Eur Heart J; 1993 Jul; 14 Suppl B():16-21. PubMed ID: 8370366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of action of various ATP-sensitive potassium channel openers.
    Grover GJ
    Cardiovasc Res; 1996 Jan; 31(1):177-9. PubMed ID: 8849605
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship of severity of myocardial stunning to ATP dependent potassium channel modulation.
    Warltier DC; Auchampach JA; Gross GJ
    J Card Surg; 1993 Mar; 8(2 Suppl):279-83. PubMed ID: 8461517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potassium channel activators in the management of ischaemic heart disease: a focus on nicorandil.
    Purcell H; Fox K
    Br J Clin Pract; 1993; 47(3):150-4. PubMed ID: 8347442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicorandil augments regional ischemia-induced monophasic action potential shortening and potassium accumulation without serious proarrhythmia.
    Miyazaki T; Moritani K; Miyoshi S; Asanagi M; Zhao LS; Mitamura H; Ogawa S
    J Cardiovasc Pharmacol; 1995 Dec; 26(6):949-56. PubMed ID: 8606533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic effects of bolus nicorandil compared with nitroglycerin.
    Utoh J; Miyauchi Y; Goto H; Obayashi H; Hirata T
    Am J Emerg Med; 1995 Sep; 13(5):610-2. PubMed ID: 7662070
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of K+ channel opening and stimulation of cyclic GMP in the vasorelaxant effects of nicorandil in isolated piglet pulmonary and mesenteric arteries: relative efficacy and interactions between both pathways.
    Pérez-Vizcaíno F; Cogolludo AL; Villamor E; Tamargo J
    Br J Pharmacol; 1998 Mar; 123(5):847-54. PubMed ID: 9535012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potassium channel openers: clinical applications in ischemic heart disease--overview of clinical efficacy of nicorandil.
    Knight C; Purcell H; Fox K
    Cardiovasc Drugs Ther; 1995 Mar; 9 Suppl 2():229-36. PubMed ID: 7647027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potassium channel activators in vasospastic angina.
    Lablanche JM; Bauters C; McFadden EP; Quandalle P; Bertrand ME
    Eur Heart J; 1993 Jul; 14 Suppl B():22-4. PubMed ID: 8370368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of the efficacy of nicorandil in patients with ischaemic heart disease using Exercise-T1-201 myocardial tomography.
    Yamazaki J; Ohsawa H; Uchi T; Iida M; Nakano H; Hosoi H; Morishita T; Yabe Y; Koyama N; Komatsu H
    Eur J Clin Pharmacol; 1993; 44(3):211-7. PubMed ID: 8491233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicorandil improves ischemic changes in epicardial ECG during short-term coronary occlusion by opening ATP-sensitive potassium channels in pigs.
    Takaoka A; Nakae I; Liu Q; Yamamoto K; Ito M; Kinoshita M
    Cardiovasc Drugs Ther; 1997 Dec; 11(6):757-66. PubMed ID: 9512871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.